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untreated patients and after radiotherapy and chemotherapy. During the past few years some epipodophyllotoxins, some A review of the literature of chemotherapy-related cases, howanthracyclines and other DNA topoisomerase II inhibitors ever, reveals 26 patients including our case, with Philadelphia have been shown to be leukemogenic, in most cases adminischromosome-positive CML, AML or ALL following chemotered in combination with an alkylating agent or a platinum therapy of a Philadelphia chromosome-negative leukemia or derivative.
1 Two independent studies have demonstrated a another malignancy, most often Hodgkin's disease [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] significant association between this type of combination ( Table 1) . One of these 26 patients was treated for Hodgkin's chemotherapy and the development of AML with balanced disease with radiotherapy and single agent chemotherapy with translocations involving chromosome bands 11q23 and vinblastin and developed CML as late as 192 months after 21q22. 2, 3 However, other balanced aberrations such as the therapy. 7 For these reasons this particular case is considered t(15;17)(q22;q12) and the inv(16)(p13q22) more rarely as unrelated to chemotherapy and excluded in our evaluation. observed in t-AML have also been related to previous chemoOf the remaining 25 patients, 22 patients had previously therapy with DNA topoisomerase II inhibitors. 1 received DNA topoisomerase II inhibitors, daunorubicin in 10 Recently, we observed a patient with Philadelphia chromocases, 13 patients had received alkylating agents and 10 some-positive CML after therapy with etoposide, cisplatin and patients radiotherapy (Table 1) . These findings raise the quesbleomycin for a germ cell tumor. This case, together with tion of a causal relationship between chemotherapy with other sporadic case reports of chemotherapy-related, late DNA topoisomerase II inhibitors and subsequent development occurring Philadelphia chromosome-positive leukemias of of leukemia with a t(9;22). various types, leads us to suggest that the development of Most of the chemotherapy-related leukemias with t(9;22) t(9;22)(q34;q11) in some of these rather rare cases may also could be suspected to represent incidental cases of de novo be related to previous therapy with DNA topoisomerase II leukemia. However, the fact that the general risk of AML folinhibitors.
lowing chemotherapy with alkylating agents or DNA topoisoIn 1991 a 41-year-old, previously healthy man developed merase II inhibitors is increased 50-to 100-fold or more, 
interest and supports our hypothesis of a common mechanism previously had received anthracyclines or epipodophyllotoxins. 24 Further studies may reveal more precisely the exact role for the development of balanced chromosome aberrations.
As far as other balanced chromosome aberrations in ALL of DNA topoisomerase II and its inhibition by cytostatic drugs in the development of leukemias with many balanced chroare concerned, a recent editorial emphasized that 10 out of 10 published cases of chemotherapy-related ALL with t(4;11) mosome aberrations including the t(9;22). Balanced translo- 20 7/M T-ALL DNR + VCR + Pred 13 T-ALL a L1 der(7)t(7;9), −9, der(7)t(7;9) + L-Asp + Ara C + Mtx +mar (q3?4;q22),−9,+der(12) ABMT 1 add(12)(p11) add(12)(q?2) Tsuchiya et al 21 10/M B-ALL, L1 (normal) VCR + Pred + Asp + Mtx + Acla + Ctx 16 B-ALL a L1 t(X;11) (p11;p15), Etop + Ctx + Ara C 7 −Y,add(3) (q29),der + L-Asp + Nimus + Pred (8) 
